Kala Pharmaceuticals, Inc. (KALA) AI Stock Analysis

Kala Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies utilizing its proprietary mucus-penetrating particles technology, with a primary focus on treating eye diseases. Its pipeline includes KPI-012, in clinical development for persistent corneal epithelial defects, as well as EYSUVIS for short-term dry eye disease symptoms and INVELTYS for post-operative ocular inflammation and pain. In preclinical development, the company is advancing KPI-287 to inhibit vascular endothelial and platelet-derived growth factors for retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. It also explores selective glucocorticoid receptor modulators.

Kala Pharmaceuticals generated $0 in revenue over the trailing twelve months ended June 30, 2026, with quarterly revenue falling 100.0% year-over-year. In FY2022, revenue declined 65.4% to $3.9M, down from $11.2M in FY2021 and $6.4M in FY2020. Gross margin contracted to 34.2% in FY2022 from 63.5% in FY2021. Operating margin was -2090.3% in FY2022, compared to -973.6% in FY2021 and -1512.6% in FY2020. Net income was -$44.8M in FY2022, improving from -$142.6M in FY2021 and -$104.3M in FY2020. Diluted EPS stood at -$2646.00 in FY2022 and -$10.71 over the trailing twelve months, with return on equity at -345.3%.

As of June 30, 2026, Kala Pharmaceuticals held $7.2M in cash and short-term investments, total assets of $10.6M, and shareholders' equity of $9.0M. The company reported a current ratio of 6.88. Operating cash flow was -$78.9M in FY2022, with free cash flow of -$79.2M, following an operating cash burn of -$108.2M in FY2021. In FY2025, capital expenditures were $15,000. Over the past five years, the company's share count changed by -94.3%.

Kala Pharmaceuticals trades at a price-to-sales ratio of 23.7x and a price-to-book ratio of 1.2x, with an enterprise value of $3.3M based on its $3.7M market capitalization. Its price-to-sales multiple of 23.7x sits well above the 4.1x median of its US-listed Healthcare peers. The peer group median trailing P/E is 24.6x and forward P/E is 17.3x. Over the past year, KALA returned -99.7%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned -100.0% versus an 83.0% gain for the S&P 500.

One analyst covers Kala Pharmaceuticals for the next fiscal year, projecting revenue of $0 and an EPS estimate of -$0.53, representing an estimated EPS growth of 88.1%. The mean analyst price target is $1.50, which is 689.9% above the last closing price of $0.19 on October 16, 2026. The company beat EPS estimates in 3 of the last 4 quarters. The next earnings date is November 18, 2026.

This page is an AI-written research summary of Kala Pharmaceuticals, Inc. (KALA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KALA income statement, KALA balance sheet, KALA key metrics, KALA analyst forecast, KALA chart. See the KALA stock overview for the latest quote and news.